{{Rsnum
|rsid=881152
|Gene=DUSP1
|Chromosome=5
|position=172771552
|Orientation=plus
|GMAF=0.1896
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=DUSP1
}}{{PMID Auto
|PMID=20673984
|Title=Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients
|OA=1
}}

{{PharmGKB
|RSID=rs881152
|Name_s=DUSP1 rs881152 G>A
|Gene_s=DUSP1
|Feature=
|Evidence=PubMed ID:20673984
|Annotation=Risk or phenotype-associated allele: GG. Phenotype: The GG genotype was associated with greater change in FEV in response to salbutamol in asthma patients with concurrent use of inhaled corticosteroids. This association was found in the GALA cohort and replicated in the SAPPHIRE cohort but not the SAGE cohort. Study size: n = 646 (GALA); n = 264 (SAGE); n = 430 (SAPPHIRE). Study population/ethnicity: Asthma; Genetics of Asthma in Latino Americans (GALA) study; Study of African Americans, Asthma, Genes &amp; Environments (SAGE); Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE); Mexican American; Puerto Rican American; Hispanic; African American. Significance metric(s): p = 0.02 (GALA). Type of association: PD.
|Drugs=beclomethasone; salbutamol
|Drug Classes=CORTICOSTEROIDS; GLUCOCORTICOIDS
|Diseases=Asthma
|Curation Level=Curated
|PharmGKB Accession ID=PA165374664
}}